Recruiting

Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic nervous system activity and blood flow during common laboratory physiological stress protocols (e.g. hypoxia, exercise), and in response to infusion of drugs that cause vasodilation or vasoconstriction.

ClinicalTrials.gov IDNCT04838678

PhaseEARLY_PHASE1

Enrollment100

SponsorUniversity of Texas Southwestern Medical Center

Age18 Years – 55 Years

SexALL

I'm interested View official listing

Conditions studied

Hypertension, Obesity

About this study

Interventions

Drug: Neuropeptide Y — intra-arterial infusion of neuropeptide Y

Primary outcomes

Blood flow measured by doppler ultrasound (Acutely on the day of study)
Muscle sympathetic nervous system activity (Acutely on the day of study)

Eligibility information

Inclusion Criteria: * Control - BMI\<30, age 18-55 * Hypertensive - BMI\<30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Obese- BMI\>30, age 18-55 Obese-hypertensive- BMI\>30, age 18-55, diagnosis of hypertension by 24-hour ambulatory blood pressure monitoring Exclusion Criteria: All groups - presence of other significant cardiovascular disease, renal disease, history of smoking, diabetes,

Study locations

University of Texas Southwestern Medical Center, Dallas, Texas 75231 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-19.